» Articles » PMID: 36266591

Clonorchis Sinensis Infection Contributes to Hepatocellular Carcinoma Progression in Rat

Overview
Journal Parasitol Res
Specialty Parasitology
Date 2022 Oct 20
PMID 36266591
Authors
Affiliations
Soon will be listed here.
Abstract

Clonorchis sinensis (C. sinensis) infection is a risk factor for cholangiocarcinoma. Whether it also contributes to the development of hepatocellular carcinoma (HCC) is still unclear. This study explored the potential relationship between C. sinensis infection and HCC. A total of 110 Sprague-Dawley rats were divided into four treatment groups, the negative control group (NC) received intragastric (i.g.) administration of saline, while the clonorchiasis group (CS) received i.g. administration of 150 C. sinensis metacercariae. The diethylnitrosamine-induced group (DEN) received intraperitoneal (i.p.) administration of DEN. The clonorchiasis DEN-induced group (CSDEN) received i.g. administration of 150 C. sinensis metacercariae followed by i.p. administration of DEN. Hematoxylin and eosin staining, immunohistochemistry, and Masson's trichrome staining were performed for histopathological analysis of the isolated tissues. RNA-seq technology and RT-PCR were employed for gene expression. In the DEN group, 15 rats survived, of which 9 developed liver cirrhosis and 7 developed HCC. In the CSDEN group, all of the 17 surviving rats developed cirrhosis, and 15 showed development of HCC. The incidence of liver cirrhosis and HCC was significantly higher in the CSDEN group than in the DEN group. KEGG pathway analysis of the differentially expressed genes suggested significant upregulation in inflammation-associated pathways. Immunohistochemistry and RT-PCR results showed significant upregulation of hepatic progenitor cell markers (CK19, SOX9, EpCAM) in the CS group compared to the NC group, as well as in the CSDEN group compared to the DEN group. Our study suggests that C. sinensis infection increases risk of HCC in a rat model by stimulating proliferation of hepatic progenitor cells.

Citing Articles

The microRNA landscape and regulatory network in Clonorchis sinensis-infected hepatocellular carcinoma: implications for tumor progression.

Wei C, Chen J, Huang T, Zhou L, Xu Y, Lin Q Parasit Vectors. 2025; 18(1):68.

PMID: 39985046 PMC: 11846337. DOI: 10.1186/s13071-025-06689-z.


SOX9: a key transcriptional regulator in organ fibrosis.

Li Y, Xing Y, Liu N, Liu B, Wang Z Front Pharmacol. 2025; 16:1507282.

PMID: 39974732 PMC: 11835943. DOI: 10.3389/fphar.2025.1507282.


Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with .

Tang Z, Wei C, Deng X, Lin Q, Hu Q, Li S Front Immunol. 2025; 15():1489077.

PMID: 39840062 PMC: 11746118. DOI: 10.3389/fimmu.2024.1489077.


Clonorchis sinensis infection induces pathological changes in feline bile duct epithelium and alters biliary microbiota composition.

Li F, Zhang Y, Li C, Li F, Gan B, Yu H Parasite. 2024; 31:53.

PMID: 39240136 PMC: 11378715. DOI: 10.1051/parasite/2024053.


Ankylosing spondylitis coexisting with infection: A case report.

Yi T, Liu W, Leng W, Wang X, Luo L World J Clin Cases. 2024; 12(5):1018-1024.

PMID: 38414593 PMC: 10895637. DOI: 10.12998/wjcc.v12.i5.1018.


References
1.
Bahk Y, Pak J . Toll-Like Receptor-Mediated Free Radical Generation in Excretory-Secretory Product-Treated Cholangiocarcinoma Cells. Korean J Parasitol. 2016; 54(5):679-684. PMC: 5127530. DOI: 10.3347/kjp.2016.54.5.679. View

2.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10(4):321-2. DOI: 10.1016/s1470-2045(09)70096-8. View

3.
Di Giosia P, Stamerra C, Giorgini P, Jamialahamdi T, Butler A, Sahebkar A . The role of nutrition in inflammaging. Ageing Res Rev. 2022; 77:101596. DOI: 10.1016/j.arr.2022.101596. View

4.
Diakos C, Charles K, McMillan D, Clarke S . Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11):e493-503. DOI: 10.1016/S1470-2045(14)70263-3. View

5.
Llovet J, Castet F, Heikenwalder M, Maini M, Mazzaferro V, Pinato D . Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021; 19(3):151-172. DOI: 10.1038/s41571-021-00573-2. View